Shelly Abell
Acute Care · Chubbuck, IDNPI 1528791969
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 16 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Novo Nordisk at 30.5% of the total. 2025 is the largest year on record at $179, more than ten times the $13 reported in 2023.
Across 16 payments — averaging $17.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$85
- Ardelyx, Inc.$41
- AstraZeneca$34
- Novartis$19
- Amgen$19
- Fresenius USA Marketing, Inc.$18
- plus $62 from 4 others
What the payments were for
- Food & beverage$278100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 4 | $85 |
| Ardelyx, Inc. | 3 | $41 |
| AstraZeneca | 2 | $34 |
| Novartis | 1 | $19 |
| Amgen | 1 | $19 |
| Fresenius USA Marketing, Inc. | 1 | $18 |
| Calliditas Therapeutics US Inc. | 1 | $17 |
| GSK | 1 | $16 |
| Nxstage Medical, Inc. | 1 | $16 |
| Vapotherm Inc | 1 | $13 |
How this compares
$278 in reported general payments places this provider in the 55th percentile of 35 acute care providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AuryxiaFerric Citrate | 19 | $20,073 |
| Sevelamer Carbonate | 25 | $4,599 |
| Carvedilol | 83 | $727 |
| Losartan Potassium | 51 | $408 |
| Amlodipine Besylate | 33 | $297 |
| Calcitriol | 19 | $286 |
| Bumetanide | 15 | $279 |
| Hydralazine Hcl | 17 | $180 |
| Furosemide | 26 | $116 |
| Sertraline Hcl | 17 | $111 |
| Spironolactone | 13 | $102 |
| Tamsulosin Hcl | 12 | $83 |
Paid to pharmacies, not to this prescriber.
Other acute care in Chubbuck
- Izabela HarutyunyanPocatello$9K
- Keely CoxMeridian$5K
- Lydia MoorBoise$3K
- Nathan BurkeBoise$3K
- Sarah FrankCoeur D Alene$2K
- Rachel DavisBoise$2K
- Ryan HarveyNampa$1K
- Matthew DubmanBoise$1K
- Kimereng KipsugeBoise$833
- Kellie WatsonBoise$705
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.